Pharmacoeconomic evaluation of the treatment of myxomatous mitral valve disease in dogs in Germany

被引:0
作者
Nautrup, Barbara Poulsen [1 ]
Van Vlaenderen, Ilse
Nautrup, Cordula Poulsen [2 ]
机构
[1] EAH Consulting, D-52428 Julich, Germany
[2] LMU Munchen, Vet Wissensch Dept, Munich, Germany
来源
KLEINTIERPRAXIS | 2010年 / 55卷 / 04期
关键词
pharmacoeconomic analysis; cost-effectiveness; pimobendan; benazepril; myxomatous mitral valve disease; CONGESTIVE-HEART-FAILURE; COST-EFFECTIVENESS ANALYSIS; BENAZEPRIL HYDROCHLORIDE; POSTHERPETIC NEURALGIA; SURVIVAL TIMES; PIMOBENDAN; GABAPENTIN; EFFICACY;
D O I
暂无
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
The aim of this pharmacoeconomic study was to estimate the cost-effectiveness of pimobendan compared to generic benazepril for the treatment of myxomatous mitral valve disease in dogs in Germany. A Markov model was developed including all the relevant disease stages and which reflected the treatment patterns used in Germany. The observation period was one year. The chosen effectiveness parameters were survival time (life days) and time without symptoms of heart insufficiency. Transition probabilities define the progression of the disease and the impact of the treatment and were mainly derived from published randomized clinical studies, The costs of drugs and veterinary services were defined from official price and veterinary tariff lists, valid as of 2009. The mean total costs of therapy were is an element of 472.21 and is an element of 285.23 for dogs on pimobendan and benazepril, respectively. During the one-year observation period, the mean survival time for dogs on pimobendan was 274 days and 129 days for dogs on benazepril. After one year, 51% of dogs on pimobendan were still alive but less than 4% of dogs on benazepril. The cost for one life day gained with pimobendan was calculated to be 1.29. The costs for one day of treatment were less with pimobendan* (is an element of 1.72) than benazepril (is an element of 2.21). Correspondingly, the lower total therapy costs associated with benazepril were merely attributed to the shorter survival times. On average, dogs on pimobendan spent 86 days without symptoms of heart insufficiency, whereas dogs on benazepril spent 15 days without symptoms. Comprehensive sensitivity analyses confirmed the robustness and transferability of the results to various dogs and different clinic structures.
引用
收藏
页码:184 / +
页数:11
相关论文
共 50 条
  • [21] Medical management of myxomatous mitral valve disease: An evidence-based veterinary medicine approach
    Burchell, Richard K.
    Schoeman, Johan
    [J]. JOURNAL OF THE SOUTH AFRICAN VETERINARY ASSOCIATION, 2014, 85 (01)
  • [22] Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study
    Boswood, Adrian
    Gordon, Sonya G.
    Haggstrom, Jens
    Vanselow, Martin
    Wess, Gerhard
    Stepien, Rebecca L.
    Oyama, Mark A.
    Keene, Bruce W.
    Bonagura, John
    MacDonald, Kristin A.
    Patteson, Mark
    Smith, Sarah
    Fox, Philip R.
    Sanderson, Karen
    Woolley, Richard
    Szatmari, Viktor
    Menaut, Pierre
    Church, Whitney M.
    O'Sullivan, M. Lynne
    Jaudon, Jean-Philippe
    Kresken, Jan-Gerd
    Rush, John
    Barrett, Kirstie A.
    Rosenthal, Steven L.
    Saunders, Ashley B.
    Ljungvall, Ingrid
    Deinert, Michael
    Bomassi, Eric
    Estrada, Amara H.
    Fernandez Del Palacio, Maria J.
    Moise, N. Sydney
    Abbott, Jonathan A.
    Fujii, Yoko
    Spier, Alan
    Luethy, Michael W.
    Santilli, Roberto A.
    Uechi, Masami
    Tidholm, Anna
    Schummer, Christoph
    Watson, Philip
    [J]. JOURNAL OF VETERINARY INTERNAL MEDICINE, 2020, 34 (03) : 1108 - 1118
  • [23] Diagnosis and management of a more advanced stage of preclinical myxomatous mitral valve disease in dogs without echocardiography
    Toaldo, M. Baron
    [J]. SCHWEIZER ARCHIV FUR TIERHEILKUNDE, 2024, 166 (12): : 619 - 631
  • [24] Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease
    Ames, M. K.
    Atkins, C. E.
    Eriksson, A.
    Hess, A. M.
    [J]. JOURNAL OF VETERINARY CARDIOLOGY, 2017, 19 (03) : 218 - 227
  • [25] Genetics of canine myxomatous mitral valve disease
    O'Brien, M. J.
    Beijerink, N. J.
    Wade, C. M.
    [J]. ANIMAL GENETICS, 2021, 52 (04) : 409 - 421
  • [26] Angiotensin-converting enzyme inhibitors in preclinical myxomatous mitral valve disease in dogs: systematic review and meta-analysis
    Donati, P.
    Tarducci, A.
    Zanatta, R.
    Verdier, N.
    Belerenian, G.
    Cordero, I.
    Villalta, C.
    Franco, J.
    Tarragona, L.
    [J]. JOURNAL OF SMALL ANIMAL PRACTICE, 2022, 63 (05) : 362 - 371
  • [27] Radiographic lung congestion scores in dogs with acute congestive heart failure caused by myxomatous mitral valve disease
    Koster, Liza
    Vogel, Jenna
    Springer, Cary M.
    Hecht, Silke
    [J]. JOURNAL OF VETERINARY INTERNAL MEDICINE, 2023, 37 (06) : 1983 - 1991
  • [28] Alteration of clinical parameters before mortality and prognostic outcomes of pulmonary hypertension in dogs with myxomatous mitral valve disease
    Channgam, Phuttipan
    Sakcamduang, Walasinee
    Chanmongkolpanit, Kittara
    Kaenchan, Pemika
    Buayam, Wasana
    Janhirun, Yada
    Phonarknguen, Rassameepen
    Tansakul, Mookmanee
    Riengvirodkij, Nattapon
    [J]. OPEN VETERINARY JOURNAL, 2024, 14 (09) : 2237 - 2249
  • [29] Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study - A Randomized Clinical Trial
    Boswood, Adrian
    Haeggstroem, Jens
    Gordon, Sonya G.
    Wess, Gerhard
    Stepiens, Rebecca L.
    Oyama, Marc A.
    Keene, Bruce W.
    Bonagura, John
    MacDonald, Kristin A.
    Patteson, Marc
    Smith, Sarah
    Fox, Philip R.
    Sanderson, Karen
    Woolley, Richard
    Szatmari, Viktor
    Menaut, Pierre
    Church, Whit M.
    O'Sullivan, M. Lynn
    Jaudon, Jean-Phillippe
    Kres-Ken, Jan-Gerd
    Rush, John
    Barrett, Kirstie A.
    Rosenthal, Steven L.
    Saunders, Ashley B.
    Ljungvall, Ingrid
    Deinert, Michael
    Bomassi, Eric
    Estrada, Amara H.
    Fernandez Del Palacio, Marie Jose
    Moise, N. Sydney
    Abbott, Jonathan A.
    Fop, Yoko
    Spier, Alan
    Luethy, Michael W.
    Santilli, Roberto A.
    Uechi, Masami
    Tidholm, Anna
    Watson, Philip
    [J]. KLEINTIERPRAXIS, 2017, 62 (02): : 64 - 87
  • [30] Echocardiographic Changes in Dogs with Stage B2 Myxomatous Mitral Valve Disease Treated with Pimobendan Monotherapy
    Crosland, Andrew
    Cortes-Sanchez, Pablo Manuel
    Sudunagunta, Siddharth
    Bouvard, Jonathan
    Bode, Elizabeth
    Culshaw, Geoff
    Dukes-McEwan, Joanna
    [J]. VETERINARY SCIENCES, 2024, 11 (12)